CEO defends $300,000-per-year cost for a drug for a rare form of muscular dystrophy

Sarepta Therapeutics CEO Doug Ingram told CNBC on Wednesday that accessing reimbursement from insurance companies for expensive, rare disease treatments is “always challenging.” But responding to a question about the $300,000-per-year cost for a Sarepta...